Paliperidone “Complete Response” Makes Two For J&J Under Two-Week-Old FDA Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
No more studies are required, but FDA outlined questions that need to be addressed, company says.
You may also be interested in...
Paliperidone Palmitate Launch Unlikely Until 2010, J&J Says
New dosing option for the atypical antipsychotic will be included in the NDA resubmission.
Paliperidone Palmitate Launch Unlikely Until 2010, J&J Says
New dosing option for the atypical antipsychotic will be included in the NDA resubmission.
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.